Akzo Nobel to transfer antithrombotic Arixtra® to Sanofi-Synthélabo

08-Jan-2004

Akzo Nobel's human healthcare business Organon and Sanofi-Synthélabo have announced that they have agreed in principle to revise the terms of their collaboration on antithrombotic Arixtra® and certain other oligosaccharides, such as idraparinux (SanOrg 34006). Pursuant to this deal, Organon will transfer to Sanofi-Synthélabo its remaining rights and development obligations for Arixtra and other oligosaccharides in exchange for revenues based on future sales.

Both companies have concluded that a single management structure will strengthen the opportunities for commercial success in the complex U.S. market for Arixtra. As part of the agreement, Organon will receive from Sanofi-Synthélabo revenues based on future sales from jointly-developed antithrombotic products.

Arixtra, the latest generation of antithrombotics, has the highest efficacy and safety profile in the prophylaxis of acute deep vein thrombosis - which may lead to pulmonary embolism - in patients undergoing hip fracture surgery, hip replacement surgery and knee replacement surgery. Idraparinux is specifically being developed for various indications such as chronic thrombosis.

Akzo Nobel expects the agreement to contribute to its profit margin over the coming years. The new agreement follows Akzo Nobel's strategic review of its pharmaceutical business last year. "It will enable us to secure profitability while focusing on the growth of therapeutic areas in which Organon has leading positions. This step aligns with our commitment to fix our pharmaceutical business group through a more focused and flexible approach," said Toon Wilderbeek, Member of Akzo Nobel's Board of Management.

https://www.chemeurope.com/en/news/33377/akzo-nobel-to-transfer-antithrombotic-arixtra-to-sanofi-synthelabo.html